Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis

Next Previous
Search
Trial Profile

A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lirentelimab (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Registrational; Therapeutic Use
  • Acronyms EoE KRYPTOS; KRYPTOS
  • Sponsors Allakos

    • Most Recent Events

    • 30 Mar 2023 Status changed from active, no longer recruiting to completed.
    • 26 Oct 2022 Primary endpoint (Mean absolute change in Dysphagia Symptom Questionnaire (DSQ) score) has been met, as per results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022.
    • 26 Oct 2022 Primary endpoint (The proportion of patients who achieve esophageal intraepithelial eosinophil count of 6 eosinophils/hpf) has been met, as per results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top